These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37854590)

  • 1. Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells.
    Wei Z; Xu J; Zhao C; Zhang M; Xu N; Kang L; Lou X; Yu L; Feng W
    Front Immunol; 2023; 14():1273507. PubMed ID: 37854590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.
    Teachey DT; Lacey SF; Shaw PA; Melenhorst JJ; Maude SL; Frey N; Pequignot E; Gonzalez VE; Chen F; Finklestein J; Barrett DM; Weiss SL; Fitzgerald JC; Berg RA; Aplenc R; Callahan C; Rheingold SR; Zheng Z; Rose-John S; White JC; Nazimuddin F; Wertheim G; Levine BL; June CH; Porter DL; Grupp SA
    Cancer Discov; 2016 Jun; 6(6):664-79. PubMed ID: 27076371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.
    Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K
    J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy.
    Liu Y; Chen X; Wang D; Li H; Huang J; Zhang Z; Qiao Y; Zhang H; Zeng Y; Tang C; Yang S; Wan X; Chen YH; Zhang Y
    J Immunother; 2018; 41(9):406-410. PubMed ID: 30198955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy.
    Gong WJ; Qiu Y; Li MH; Chen LY; Li YY; Yu JQ; Kang LQ; Sun AN; Wu DP; Yu L; Xue SL
    Front Immunol; 2022; 13():922212. PubMed ID: 36105799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].
    Du MY; Zhang YQ; Liao DY; Xie W; Xiong W; Mei H; Hu Y
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):793-799. PubMed ID: 38049329
    [No Abstract]   [Full Text] [Related]  

  • 8. Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy.
    Luo H; Wang N; Huang L; Zhou X; Jin J; Li C; Wang D; Xu B; Xu J; Jiang L; Wang J; Cao Y; Xiao Y; Zhang Q; Mao X; Liu S; Chen L; Xiao M; Zhou J
    J Immunother Cancer; 2019 Oct; 7(1):271. PubMed ID: 31640816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
    Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
    Front Immunol; 2021; 12():611366. PubMed ID: 33708205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
    Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
    Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of Chimeric Antigen Receptor T Cell in the Treatment of Refractory/Recurrent B Acute Lymphocytic Leukemia in Children].
    Yang F; Wang TY; DU WW; He HL; Xiao PF; Lu Y; Hu SY; Li BS; Lu J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):718-725. PubMed ID: 35680795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of anti-CD19 chimeric antigen receptor T cell therapy in children with relapsed or refractory acute B-lymphocytic leukemia and its prognosis.
    Li N; Li H
    J BUON; 2021; 26(1):159-165. PubMed ID: 33721447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double systemic cytokine release syndrome following sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells after autologous hematopoietic stem cell transplantation for a central diffuse large B-cell lymphoma patient: A case report and literature review.
    Zheng J; Xiao Y; Wu XQ; Xiao QZ; Feng C; Gao KB
    Front Immunol; 2023; 14():1098815. PubMed ID: 36798130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment and predictive ability of the absolute neutrophil count in peripheral blood for in vivo CAR T cells expansion and CRS.
    Zhang M; Long X; Xiao Y; Jin J; Chen C; Meng J; Liu W; Liu A; Chen L
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38016717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
    Hay KA
    Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
    Kotch C; Barrett D; Teachey DT
    Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
    [No Abstract]   [Full Text] [Related]  

  • 17. Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study.
    Zhou L; Fu W; Wu S; Xu K; Qiu L; Xu Y; Yan X; Zhang Q; Zhang M; Wang L; Hong R; Chang AH; Yu J; Fu S; Kong D; Li L; Wang Y; Li Z; Jiang H; Huang J; Liu Z; Su N; Wei G; Hu Y; Huang H
    Br J Haematol; 2023 Aug; 202(3):517-524. PubMed ID: 37192741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
    Hay KA; Hanafi LA; Li D; Gust J; Liles WC; Wurfel MM; López JA; Chen J; Chung D; Harju-Baker S; Cherian S; Chen X; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2017 Nov; 130(21):2295-2306. PubMed ID: 28924019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.
    Zhou J; Zhang Y; Shan M; Zong X; Geng H; Li J; Chen G; Yu L; Xu Y; Li C; Wu D
    Front Immunol; 2022; 13():997589. PubMed ID: 36131934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy.
    Jiang H; Liu L; Guo T; Wu Y; Ai L; Deng J; Dong J; Mei H; Hu Y
    Ann Hematol; 2019 Jul; 98(7):1721-1732. PubMed ID: 31055613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.